First-trimester glycaemic markers as predictors of gestational diabetes and its associated adverse outcomes: A prospective cohort study.

HbA1c fetal growth gestational diabetes mellitus large for gestational age macrosomia preeclampsia pregnancy-induced hypertension

Journal

Diabetic medicine : a journal of the British Diabetic Association
ISSN: 1464-5491
Titre abrégé: Diabet Med
Pays: England
ID NLM: 8500858

Informations de publication

Date de publication:
02 2023
Historique:
revised: 18 10 2022
received: 24 06 2022
accepted: 30 11 2022
pubmed: 2 12 2022
medline: 17 1 2023
entrez: 1 12 2022
Statut: ppublish

Résumé

Gestational diabetes mellitus (GDM) is associated with excessive fetal growth in later gestation. Recent data suggest accelerated growth may begin before 28 weeks' gestation when GDM is typically diagnosed. The identification of pregnancies at risk of early fetal growth would enable early intervention. We assessed the use of early pregnancy HbA1c in predicting excessive fetal growth. Women were recruited at antenatal booking from a major maternity unit in the UK. HbA1c was measured at <14 weeks gestation in 1243 women at risk of GDM as defined by UK NICE risk factors of whom 1115 underwent OGTT. Women with previous GDM were excluded. Comprehensive fetal ultrasound was performed at 28 weeks' gestation alongside 75 g OGTT in 976 of these women. GDM was defined using WHO criteria. Pregnancy outcomes were extracted from the regional maternity care database. Two hundred and thirty-six women screened positive for GDM. At diagnosis, GDM pregnancies demonstrated higher adjusted fetal weight percentile than non-GDM pregnancies: (51.8 vs. 46.3, p = 0.008). This was driven by increases in the fetal abdominal circumference percentile in GDM compared with non-GDM pregnancies (55.3 vs. 46.2, p = <0.001). Early pregnancy HbA1c was higher in the GDM versus non-GDM group: (35.7 mmol/mol vs. 32.9 mmol/mol p = <0.01). A threshold for predicting excessive fetal growth was not identified in this cohort. Accelerated fetal growth is evident prior to the diagnosis of GDM. There remains a need for suitable methods of early identification of pregnancies at high risk for early accelerated fetal growth due to GDM. First-trimester HbA1c was not useful in identifying these pregnancies. WHAT IS ALREADY KNOWN?: Recent research suggests excessive growth associated with GDM may begin prior to 28 weeks' gestation, when GDM is typically tested for WHAT THIS STUDY HAS FOUND?: Pregnancies affected by GDM are already subject to accelerated fetal growth in comparison to non-GDM pregnancies by way of higher estimated fetal weight and fetal abdominal circumference Neither first-trimester HbA1c nor plasma glucose was useful predictors of these outcomes WHAT ARE THE IMPLICATIONS OF THIS STUDY?: Highlights the emergence of excessive growth prior to detection of GDM Reinforces need for suitable methods of identifying such pregnancies in earlier gestation.

Identifiants

pubmed: 36453695
doi: 10.1111/dme.15019
pmc: PMC10107539
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e15019

Subventions

Organisme : Public Health Agency Northern Ireland

Informations de copyright

© 2022 The Authors. Diabetic Medicine published by John Wiley & Sons Ltd on behalf of Diabetes UK.

Références

J Clin Endocrinol Metab. 2017 Feb 01;102(2):390-397
pubmed: 27880069
Aust N Z J Obstet Gynaecol. 2014 Apr;54(2):177-80
pubmed: 24359339
Am J Obstet Gynecol. 2014 Dec;211(6):641.e1-7
pubmed: 24912095
Diabet Med. 2023 Feb;40(2):e15019
pubmed: 36453695
Diabetes Res Clin Pract. 2015 Jul;109(1):135-40
pubmed: 25958098
Diabetes Care. 2012 Mar;35(3):574-80
pubmed: 22301123
Diabet Med. 2014 Oct;31(10):1277
pubmed: 24909056
Diabetes Care. 2011 Aug;34(8):1683-8
pubmed: 21636798
Diabetes Res Clin Pract. 2020 Sep;167:108353
pubmed: 32739381
Diabetes Care. 2016 Jun;39(6):982-7
pubmed: 27208333
Radiology. 1991 Oct;181(1):129-33
pubmed: 1887021
Diabetes Res Clin Pract. 2017 Nov;133:85-91
pubmed: 28918341
Diabetes Care. 2014 Nov;37(11):2953-9
pubmed: 25190675

Auteurs

Robert J D'Arcy (RJ)

Regional Centre for Endocrinology, Royal Victoria Hospital, Belfast, UK.
Centre for Public Health, Queens University Belfast, UK.

Inez E Cooke (IE)

Royal Jubilee Maternity Service, Belfast, UK.

Michelle McKinley (M)

Centre for Public Health, Queens University Belfast, UK.

David R McCance (DR)

Regional Centre for Endocrinology, Royal Victoria Hospital, Belfast, UK.

Una M Graham (UM)

Regional Centre for Endocrinology, Royal Victoria Hospital, Belfast, UK.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH